Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Postoperative Care
Interventions: capnostream 20, Oridian Medical 1987 ltd, Needham MA; Device
Lead sponsor: Allenmore Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
Interventions: Aquamantys, standard electrocautery (Bovie); Device
Lead sponsor: Joint Implant Surgeons, Inc.; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Albany, Ohio

Conditions: Breast Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Thoracic Cancer, Genitourinary Cancer
Interventions: Clinician Nudge Email, Patient Nudge Letter and Share questionaire; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Leg Ulcer, Diabetic Foot Ulcer
Interventions: Wound dressing; Device
Lead sponsor: Omeza, LLC; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Jacksonville, Florida • Newark, New Jersey • Portland, Oregon + 1 more

Conditions: Breast Cancer
Interventions: Tamoxifen, Lumpectomy, brachytherapy; Drug · Procedure · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Nashville, Tennessee • Houston, Texas

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: questionnaire administration, exercise intervention, quality-of-life assessment, survey administration, management of therapy complications, psychosocial assessment and care; Other · Behavioral · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetic Foot Ulcer
Interventions: Tenex TXB MicroTip Ultrasound system plus SOC, Standard of Care for diabetic foot ulcer; Device · Other
Lead sponsor: Tenex Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Mobile, Alabama • St. George, Utah

Conditions: Breast Cancer
Interventions: herceptin, carboplatin, docetaxel, conventional surgery, radiation therapy; Biological · Drug · Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: East Brunswick, New Jersey • Freehold, New Jersey • Hamilton, New Jersey + 5 more

Conditions: Cutaneous Squamous Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma of the Skin, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma
Interventions: Cemiplimab, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Aurora, Colorado • Tampa, Florida • Basking Ridge, New Jersey + 10 more

Conditions: Breast Cancer, Non-small Cell Lung Carcinoma
Interventions: Trastuzumab deruxtecan (DS-8201a), Pembrolizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more

Conditions: Pain, Anxiety
Interventions: Synera; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Psoriasis
Interventions: Mirikizumab, Placebo, Secukinumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 42
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more

Conditions: HER2+/HR+ Breast Cancer
Interventions: ZW25 (Zanidatamab), Palbociclib, Fulvestrant; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Santa Monica, California • Nashville, Tennessee • Seattle, Washington

Conditions: Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Interventions: ABM-168; Drug
Lead sponsor: ABM Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: San Francisco, California • Indianapolis, Indiana • New Brunswick, New Jersey + 3 more

Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions: behavioral dietary and exercise intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 65 Years to 120 Years
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Interventions: geko device; Device
Lead sponsor: Firstkind Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Invasive Breast Cancer
Interventions: [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Counseling
Interventions: focus group & questionaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years to 20 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Gynecologic Cancer, Gastrointestinal Cancer
Interventions: Survey, Saliva sample, Smoking Status questions; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions: Olaparib, Physician's choice chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 42
States / cities: San Diego, California • Santa Rosa, California • Whittier, California + 35 more

Conditions: Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Conditions: Systemic Lupus Erythematosus
Interventions: Sifalimumab; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 24
States / cities: Anniston, Alabama • Scottsdale, Arizona • San Leandro, California + 21 more

Search by objective public record fields.

The Comparison of Pulse Oximetry, End-tidal Capnometry, and Integrated Pulmonary Index (IPI)

Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

The Omeza Protocol for Chronic Ulcers

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors

Prospective, Multicenter, RCT of the Tenex Ultrasound System

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Study of Use of Synera for Pain During Local Skin Infiltration With Lidocaine Before Epidural Placement

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight

Geko™ Cross Therapy Registry - Wound

FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer

Improving Evidence-Based Care for Cancer Patients

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis